

# Neophytos Kouphou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4763197/publications.pdf>

Version: 2024-02-01

7  
papers

1,518  
citations

1478505

6  
h-index

1720034

7  
g-index

9  
all docs

9  
docs citations

9  
times ranked

4910  
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , 2020, 5, 1598-1607.	13.3	1,115
2	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	14.3	112
3	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020, 16, e1008817.	4.7	105
4	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	13.3	94
5	Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. <i>Journal of Infection</i> , 2020, 81, 931-936.	3.3	59
6	ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type composition—implications for COVID-19. <i>International Journal of Obesity</i> , 2022, 46, 1478-1486.	3.4	18
7	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. <i>PLoS ONE</i> , 2021, 16, e0249791.	2.5	6